ERBB2 and breast cancer: Trastuzumab (Herceptin Roche, Basel, Switzerland), a humanised monoclonal antibody with specificity for HER2, changed the natural history of HER2 overexpressing breast cancer, in the adjuvant setting as well as in metastatic disease.